Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open‐label study

Simone, Clara De; Maiorino, Alessia; Tassone, F.; D’agostino, M. A.; Caldarola, Giacomo

doi:10.1111/j.1468-3083.2012.04642.x

Cited by 47 publications

(33 citation statements)

References 15 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tacrolimus in 0.1% and 0.03% ointment was found to be effective in psoriasis due to its immunosuppressive property. De Simone et al [19] have reported good clinical results in nail psoriasis with topical tacrolimus 0.1% ointment application after 12 weeks. It seemed to be equally effective on nail bed and matrix lesions without having severe side effects.…”

Section: Topical Therapymentioning

confidence: 99%

Treatment of Nail Psoriasis: Common Concepts and New Trends

Oram

Akkaya

2013

Dermatology Research and Practice

View full text Add to dashboard Cite

The lifetime incidence of nail involvement in psoriatic patients is estimated to be 80–90%, and the nails can be affected in 10% to 55% of psoriatic patients. Psoriasis may also solely involve the nails, without any other skin findings, in which the treatment can be more challenging. Nail psoriasis may lead to considerable impairment in quality of life due to aesthetic concerns and more importantly limitations in daily activities resulting from the associated pain, which may be overlooked by the physicians. Several topical and systemic treatment modalities, as well as radiation and light systems, have been used in the treatment of nail psoriasis. In the last decade, the introduction of biologic agents and the utilization of laser systems have brought a new insight into the treatment of nail psoriasis. This paper focuses on the recent advances, as well as the conventional methods, in treating nail psoriasis in adults and children, in reference to an extensive literature search.

show abstract

Section: Topical Therapymentioning

confidence: 99%

Treatment of Nail Psoriasis: Common Concepts and New Trends

Oram

Akkaya

2013

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…1a) is a potent immunosuppressive agent used clinically to reduce the risk of organ rejection in postoperative transplants patients (1). It is also used to treat different skin disorders such as atopic dermatitis (2), psoriasis (3), and vitiligo (4). Although both tacrolimus and cyclosporine A (CyA; Fig.…”

Section: Introductionmentioning

confidence: 99%

Reutilization of Tacrolimus Extracted from Expired Prograf® Capsules: Physical, Chemical, and Pharmacological Assessment

et al. 2015

View full text Add to dashboard Cite

Abstract. In this study, we investigated whether tacrolimus extracted and purified from the commercial capsules (Prograf® 5 mg) have retained its original quality and activity beyond the capsules expiration date in order to be reused for research purposes after extraction. High-performance liquid chromatography (HPLC) assay method was developed and validated for the quantification of tacrolimus, using cyclosporine A as an internal standard (IS). Moreover, a combination of analytical methods, including nuclear magnetic resonance (NMR), gas chromatography-mass spectrometry (GC-MS), Fourier transform-infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), and differential scanning calorimetry (DSC) were used to assess the quality of extracted/purified tacrolimus. Suppression of murine peripheralblood mononuclear cells (PBMC) proliferation and the levels of interleukin-2 (IL-2) and interferon gamma (IFN-γ) were also assessed. The data obtained showed no detectable differences in the quality profile between the authentic sample and extracted drug. Also, the results showed that the extracted/ purified tacrolimus was able to suppress T cell proliferation, induced by concanavalin A, indicating the retained pharmacological activity. We proved that tacrolimus extracted/purified from expired Prograf® capsuled retains its purity and immunosuppressive activity and can be reused for research and possibly in pharmaceutical manufacturing.

show abstract

“…Hatta fleksural ve fasiyal psoriasiste topikal takrolimus topikal klobetazol butirat ve mometazon furat gibi topikal steroidlere sırasıyla eşdeğer ve üstün bulunmuştur 7,8 . Aslında büyük molekül ağırlığına rağmen ilginç olarak takrolimus tırnak psoriasisinde de denenmiş ve etkili bulunmuştur 13 . İlacın turnak bariyerini lipofilik yapısı ve merhem formunda olması nedeniyle geçebildiği düşünülmüştür.…”

Section: Discussionunclassified

“…Bunun yanında kronik plak tipi psoriasiste etkinliği plaseboya benzer, plasebodan üstün ve potent steroidlere eşdeğer şeklinde çelişkili sonuçlar bildirilmektedir [10][11][12] . Son yıllarda topikal takrolimus tırnak tutulumunda da etkili olarak bildirilmiştir 13 . Çalışmamızda plak tipi psoriasisli hastalarda topikal tedavide alternatif bir seçenek olarak takrolimusun mevcut tedavilerle karşılaştırmalı olarak etkinliği ve güvenilirliğini incelemeyi amaçladık.…”

Section: Introductionunclassified

Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study

Kaçar¹,

Başkan²,

Bolca³

et al. 2015

TURKDERM

View full text Add to dashboard Cite

Background and Design: Despite the development of effective systemic treatments and new biological agents for psoriasis nowadays, topical medications are still the mainstay of treatment. Topical calcineurin inhibitors are currently used in various skin diseases. We investigated the efficacy and safety of tacrolimus, which is an alternative in topical treatment, in comparison with the present medications in plaque psoriasis. Materials and Methods: This prospective double-blind placebo-controlled study was conducted in 24 patients with the diagnosis of plaque psoriasis who were seen in Uludağ University Hospital dermatology outpatient clinic. 0.1% tacrolimus ointment, 0.1% mometasone furoate ointment, 0.005% calcipotriol ointment and placebo in encrypted bottles were randomly applied under occlusion to 27 psoriatic plaques in test chambers, every other day, for a period of 19 days. Clinic sum scores, side effects, and epidermal thickness measured by superficial ultrasound were noted before and after treatment in all microplaques. Besides, histopathologic scoring and epidermal thickness were measured in 9 patients at the end of the study. Results: The clinic sum scores and ultrasonographic epidermal thickness at the end were both significantly lower than the beginning values in all microplaques (p<0.05). The reduction in these two values with tacrolimus were significantly higher than that with placebo (p<0.001), but no difference was observed with calcipotriol (p=0.287, p=0.813, respectively). On the other hand, the reduction in these values with mometasone

show abstract

Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open‐label study

Abstract: Our study showed that tacrolimus 0.1% ointment may be an efficacious and safe therapeutic opportunity in the treatment of nail psoriasis. Our data should be confirmed by a double-blind study with a larger sample of patients.

Cited by 47 publications

References 15 publications

Treatment of Nail Psoriasis: Common Concepts and New Trends

Treatment of Nail Psoriasis: Common Concepts and New Trends

Reutilization of Tacrolimus Extracted from Expired Prograf® Capsules: Physical, Chemical, and Pharmacological Assessment

Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study

Contact Info

Product

Resources

About